[1] 刘晓明,邹 尧,王慧君,等.CCLG-2008方案治疗标危中危儿童急性淋巴细胞白血病中期随访结果[J].中华儿科杂志,2014,25(6):449-454.
[2] 张 钰,张艳丽,李 欣,等.CCLG-ALL-2008方案治疗169例儿童急性淋巴细胞白血病长期随访结果[J].华中科技大学学报(医学版),2016,45(4):411-419.
[3] Gaynon P S, Angiolilllo A L, Carroll W L, et al. Long term results of the children’s cancers group studies for childhood acute lymphoblastic leukemia 1983-2002: a Childrens’ Oncology Group report[J].Leukemia, 2010,24(3):285-297.
[4] 鲍萍萍,郑 莹,王春芳,等.2002-2004年上海市儿童恶性肿瘤发病特征[J].中国肿瘤,2009,18(2):119-122.
[5] National Cancer Institute. SEER Cancer Statistics Review,1975-2010[EB/OL].[2013-06-14].http //seer. Cancer.gov/csr/1975-2010
[6] Rodriguez Galindo C,Friedrich P,Alcasabas P,et al.To-ward the cure of all children with cancer through collabo-rative efforts:pediatric oncology as a global challenge[J].J Clin Oncol,2015,33(27):3065-3073.
[7] 鲍萍萍,李 凯,吴春晓,等. 2002-2010 年上海市户籍儿童恶性实体肿瘤发病特征和变化趋势分析[J]. 中华小儿外科杂志,2013,51(4):288-294.
[8] 廖玮玮,何志旭.1147例儿童实体瘤临床特征分析[J].贵州医科大学学报,2017,42(10):1227-1232.
[9] 乔 健,李作青,潘翠玲,等.婴儿期恶性实体瘤诊治特点的临床分析[J].中华小儿外科杂志,2014,35(6):475-478.
[10] Ries L A G, Reichman M E, Lewis D R, et al. Cancer Survival and Incidence from the Surveillance, Epidemiology, and End Results (SEER) Program[J]. Oncologist, 2003, 8(6):541.
[11] 佚 名. 我国儿童肿瘤5年生存率超过70% 白血病居儿童肿瘤发病和死亡首位[J]. 中国肿瘤临床与康复, 2014(11):1364-1364.
[12] Rodriguez Galindo C,Friedrich P,Alcasabas P,et al.To-ward the cure of all children with cancer through collabo-rative efforts:pediatric oncology as a global challenge[J].J Clin Oncol,2015,33(27):3065-3073.
[13] Lupo P J,Nousome D,Okcu M F,et al.Maternal variation in EPHXl,a xenobiotic metabolism gene,is associated with childhoodmedulloblastoma:an exploratory case-par-ent triad study[J].Pediatric Hematol Oncol,2012,29(8):679-685.
[14] Watt T C,Inskip P D,Stratton K,et al.Radiation-relatedrisk of basal cell carcinoma:a report from the Childhood Cancer Survivor Study[J].J Natl Cancer Inst,2012,104 (16):1240-1250.
[15] Council On Environmental Health. Pesticide exposure in children [J].Pediatrics,2012,130(6):1757-1763.
[16] Zheng J, Li H, Zhu H, et al. Genistein inhibits estradiol and environmental endocrine disruptor-induced growth effects on neuroblastoma cells in vitro[J]. Oncol Lett,2013,5(5):1583-1586.
[17] Iacob D, Serban A, Fufezan O, et al. Mixed hepatoblastoma in child, case report[J]. Med Ultrason, 2014, 12(2): 157-162.
[18] Chung E M, Lattin Jr G E, Cube R, et al. From the archives of the AFIP: pediatric liver masses radiologic pathologic correlation malignant tumors[J]. Radiographics, 2011, 39(2): 483-507.
[19] Ricard F, Cimarelli S, Deshayes E, et al. Additional benifit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma[J]. Clin Nucl Med,2011,36: 672-677.
[20] London K, Stege C, Cross S, et al. 18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors[J]. Pediatr Radiol,2012,42: 418-430.
[21] Boltor R R, Omar W S, Mousa E, et al. A preliminary report on the impact of 18F-FDG PET/CT in the management of pediatric head and neck cancer[J]. Nucl Med Commun,2012,33: 21-28.
[22] Klenk C, Gawande R, Usu L, et al. Ionising radiation-free wholebody MRI versus 18F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, no-randomised, single-centre study[J]. Lancet Oncol,2014,15: 275-285.
[23] AI-Bulushi N K, Abouzied M E. Comparison of ¹⁸F-FDG PET/CT scan and 99Tcm -MDP bone scintigraphy in detecting bonemetastasis in head and neck tumors[J]. Nucl Med Commun, 2016, 37(6): 583-588.
[24] Gabriele D, Collura D,Oderda M, et al. Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database[J]. World J Urol, 2016, 34(4): 517-523.
[25] Hillner B E, Eiegel B A, Hanna L. 18F-Fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry[J]. J Nucl Med, 2015, 56(2): 222-228.
[26] Fassina A, Klijanienko J. Multidisciplinary and multimodal diagnostic approach in paediatric tumours combining fine needle aspiration, core needle biopsy and ancillary techniques[J]. Cytopathology, 2014, 25(1):3.
[27] 宋建明, 陈卫坚, 张 文,等. 外周神经母细胞性肿瘤病理诊断共识[J]. 中华病理学杂志, 2017, 46(7):459-464.
[28] 中国抗癌协会小儿肿瘤专业委员会. 儿童肝母细胞瘤多学科诊疗专家共识(CCCG-HB-2016)[J]. 中华小儿外科杂志, 2017, 38(10):102.
[29] 中国抗癌协会小儿肿瘤专业委员会. 儿童肾母细胞瘤诊断治疗建议(CCCG-WT-2016)[J]. 中华儿科杂志, 2017, 55(2):90-94.
[30] 中国抗癌协会小儿肿瘤专业委员会. 中国儿童及青少年横纹肌肉瘤诊疗建议(CCCG-RMS-2016)[J]. 中华儿科杂志, 2017, 55(10):106.
[31] 中国抗癌协会小儿肿瘤专业委员会. 儿童神经母细胞瘤诊疗专家共识[J]. 中华小儿外科杂志, 2015, 36(1):3-7.
[32] 吴晔明. 儿童恶性实体肿瘤需要多学科合作的规范化治疗[J]. 临床小儿外科杂志, 2013, 12(2):83-84.
[33] Park J R, Bagatell R, Cohn S L, et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the national cancer institute clinical trials planning meeting[J]. J Clin Oncol, 2017, 35 (22): 2580-2587.
[34] Whittle S B, Smith V, Doherty E, et al. Overview and recent advances in the treatment of neuroblastoma[J]. Expert Rev Anticancer Ther, 2017,17(4): 369-386.
[35] Esposito M R, Aveic S, Seydel A, et al. Neuroblastoma treatment in the post-genomic era[J]. J Biomed Sci, 2017, 24(1): 14.
[36] 中国抗癌协会儿科专业委员会. 儿童肾肿瘤多中心协作方案诊治随访报告[J]. 中华儿科杂志, 2016, 54(11):808-813.
[37] 汤梦婕, 袁晓军,谈 珍,等. 多学科综合治疗47例儿童肝母细胞瘤的疗效评估[J]. 中华实用儿科临床杂志, 2016, 31(15):1175-1179.
[38] Cai J, Pan C, Lu Q, et al. Childhood renal tumor: a report from a Chinese Children’s Cancer Group[J]. Biomed Res Inter, 2016, 2014:894341.
[38] Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma[J]. Expert Rev Anticancer Ther, 2017, 17(10): 889-904.
[40] Siebert N, Zumpe M, Juttner M, et al. PD-1blockade augments anti-neuroblastoma immune response induced byanti-GD2 antibody ch14.18/CHO[J]. Oncoimmunology, 2017, 6 (10): e1343775.
[41] Ladenstein S, Weixler B, Baykan M, et al. Ch14. 18antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study[J]. mAbs, 2013, 5 (5):801-809.
[42] Yu A L, Gilman A L, Ozkaynak M F, et al. Children’s Oncology, Anti-GD2 antibody with GM-CSF interleukin-2, and isotretinoin for neuroblastoma[J]. N Engl J Med, 2010, 363(14): 1324-1334.